Efalizumab-induced severe thrombocytopenia can be resolved

Biologics: Targets and Therapy

Volumn 2, Issue 4, 2008, Pages 923-927

  Prignano, Francesca ^a   Zanieri, F ^a   Mokhtarzadeh, S ^a   Lotti, T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Efalizumab; Psoriasis; Thrombocytopenia

Indexed keywords

EID: 82255182933     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s4377     Document Type: Article

References (13)

1. Christophers E. 2001. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol, 26:314-20.
2. Gordon KB, Papp KA, Hamilton TK, et al. 2003. Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randimized controlled trial. JAMA, 290:3073-80.
3. Gottlieb AB, Gordon KB, Lebwohl MG, et al. Efalizumab Study Group. 2004. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe plaque psoriasis. J Drugs Dermatol, 3:27-38.
4. Grim Hostetler S, Zirwas M, Bechtel MA. 2007. Efalizumab-associated thrombocytopenia. J Am Acad Dermatol, 57:707-10.
5. Krueger GG, Bergstresser PR, Lowe NJ, et al. 1984. Psoriasis. J Am Acad Dermatol, 11:937-47.
6. Krueger JG, Bowcock A. 2005. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis, 64:30-6.
7. Leonardi C, Menter A, Hamilton T, et al. 2008. Efalizumab:results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol, 158:1107-16.
8. Leonardi CL. Papp KA, Gordon KB et al. 2005. Efalizumab Study Group. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol, 52:425-33.
9. Menter A, Gordon KB, Carey W, et al. 2005. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. (Reprinted) Arch Dermatol, 141:31-8.
10. Pearce DJ, Higgins KB, Stealey KH, et al. 2006. Adverse events from systemic therapies for psoriasis are common in clinical practice. J Dermatol Treat, 17:288-93.
11. Prignano F, Buggiani G, Lotti T. 2008. Efalizumab in the treatment of psoriasis: when comorbidity is an issue. Dermatol Ther, 21:S25-S9.
12. Scheinfeld N. 2006. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf, 5:197-209.
13. Van den Bemt PM, Meyboom R, Egberts A. 2004. Drug-induced immune thrombocytopenia. Drug Saf, 27:1243-52.